Bluebird Bio Company Insiders
BLUE Stock | USD 0.39 0.03 6.76% |
Bluebird Bio's insiders are aggressively selling. The analysis of the overall insider sentiment regarding Bluebird bio suggests that all insiders are panicking. Bluebird Bio employs about 375 people. The company is managed by 15 executives with a total tenure of roughly 6 years, averaging almost 0.0 years of service per executive, having 25.0 employees per reported executive.
Bluebird Bio's Insider Buying Vs Selling
0
Selling | Buying |
Latest Trades
2024-02-05 | Thomas J Klima | Disposed 2714 @ 0.9 | View | ||
2024-01-05 | Richard A Colvin | Disposed 597 @ 1.42 | View |
Monitoring Bluebird Bio's insider sentiment can offer insights into its future performance, as insiders often have access to more information about their company's operations, financial health, and upcoming initiatives than the general public. However, it's essential to note that insider trading is regulated by securities laws, and insiders are required to disclose their trades publicly to ensure transparency and prevent unfair advantages based on non-public information.
Bluebird |
Bluebird Bio Management Team Effectiveness
The company has return on total asset (ROA) of (0.3624) % which means that it has lost $0.3624 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.867) %, meaning that it created substantial loss on money invested by shareholders. Bluebird Bio's management efficiency ratios could be used to measure how well Bluebird Bio manages its routine affairs as well as how well it operates its assets and liabilities. As of December 11, 2024, Return On Tangible Assets is expected to decline to -0.37. In addition to that, Return On Capital Employed is expected to decline to -0.61. At present, Bluebird Bio's Non Current Assets Total are projected to increase significantly based on the last few years of reporting. The current year's Intangible Assets is expected to grow to about 10.8 M, whereas Other Assets are forecasted to decline to about 33.2 M.The current year's Common Stock Shares Outstanding is expected to grow to about 202.4 M, whereas Net Loss is forecasted to decline to (251.9 M).
Bluebird Bio Workforce Comparison
Bluebird bio is rated below average in number of employees category among its peers. The total workforce of Health Care industry is currently estimated at about 7,431. Bluebird Bio holds roughly 375 in number of employees claiming about 5% of equities under Health Care industry.
Bluebird Bio Insider Trading
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Bluebird Bio insiders, such as employees or executives, is commonly permitted as long as it does not rely on Bluebird Bio's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Bluebird Bio insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Colvin Richard A over three months ago Disposition of 2343 shares by Colvin Richard A of Bluebird Bio at 2.9769 subject to Rule 16b-3 | ||
Sterling O. James over three months ago Acquisition by Sterling O. James of 300000 shares of Bluebird Bio at 0.98 subject to Rule 16b-3 | ||
Cloonan Michael over three months ago Insider Trading | ||
Jeffrey Walsh over six months ago Sale by Jeffrey Walsh of 300 shares of Bluebird Bio | ||
Jeffrey Walsh over six months ago Exercise or conversion by Jeffrey Walsh of 100 shares of Bluebird Bio subject to Rule 16b-3 | ||
Jeffrey Walsh over a year ago Sale by Jeffrey Walsh of 200 shares of Bluebird Bio | ||
Jeffrey Walsh over a year ago Sale by Jeffrey Walsh of 100 shares of Bluebird Bio |
Bluebird Bio Notable Stakeholders
A Bluebird Bio stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Bluebird Bio often face trade-offs trying to please all of them. Bluebird Bio's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Bluebird Bio's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
Andrew Obenshain | CEO President | Profile | |
Oliver III | CFO Officer | Profile | |
Elizabeth Pingpank | Director Communications | Profile | |
Mr MD | Chief Officer | Profile | |
Melissa Bonner | VP Research | Profile | |
Andrea Walton | Chief Officer | Profile | |
JD Esq | Chief Secretary | Profile | |
Christopher CPA | Principal CFO | Profile | |
Richard MD | Chief Officer | Profile | |
Jess Rowlands | Head Communications | Profile | |
Liviu MD | VP Affairs | Profile | |
Kasra Kasraian | Senior Operations | Profile | |
Scott Shoemaker | Senior Quality | Profile | |
Sarah Alspach | Senior Affairs | Profile | |
Thomas Klima | Chief COO | Profile |
About Bluebird Bio Management Performance
The success or failure of an entity such as Bluebird bio often depends on how effective the management is. Bluebird Bio management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Bluebird management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Bluebird management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Last Reported | Projected for Next Year | ||
Return On Tangible Assets | (0.35) | (0.37) | |
Return On Capital Employed | (0.58) | (0.61) | |
Return On Assets | (0.34) | (0.36) | |
Return On Equity | (1.09) | (1.03) |
Please note, the presentation of Bluebird Bio's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Bluebird Bio's management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Bluebird Bio's management manipulating its earnings.
Bluebird Bio Workforce Analysis
Traditionally, organizations such as Bluebird Bio use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Bluebird Bio within its industry.Bluebird Bio Manpower Efficiency
Return on Bluebird Bio Manpower
Revenue Per Employee | 78.7K | |
Revenue Per Executive | 2M | |
Net Loss Per Employee | 565.1K | |
Net Loss Per Executive | 14.1M | |
Working Capital Per Employee | 217.5K | |
Working Capital Per Executive | 5.4M |
Complementary Tools for Bluebird Stock analysis
When running Bluebird Bio's price analysis, check to measure Bluebird Bio's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Bluebird Bio is operating at the current time. Most of Bluebird Bio's value examination focuses on studying past and present price action to predict the probability of Bluebird Bio's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Bluebird Bio's price. Additionally, you may evaluate how the addition of Bluebird Bio to your portfolios can decrease your overall portfolio volatility.
Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
Content Syndication Quickly integrate customizable finance content to your own investment portal | |
Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
Share Portfolio Track or share privately all of your investments from the convenience of any device | |
Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments |